Hindawi Disease Markers Volume 2020, Article ID 8847986, 17 pages https://doi.org/10.1155/2020/8847986 Research Article eRNAs and Superenhancer lncRNAs Are Functional in Human Prostate Cancer Xiaona Zhang,1,2,3 Panpan Pang,2,3,4 Min Jiang,1,2,3 Qunfa Cao,2,3 Huili Li,2,3 Yi Xu,5 Yao Li ,4 Xue Chen ,1 and Junsong Han 2,3 1Department of Pathology, Tongji Hospital, Tongji University School of Medicine, Shanghai, China 2National Engineering Center for Biochip at Shanghai, Shanghai, China 3Shanghai Biochip Corporation, Shanghai, China 4Shanghai Engineering Research Center of Industrial Microorganisms, School of Life Science, Fudan University, Shanghai, China 5Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Chinese Medicine, Shanghai, China Correspondence should be addressed to Yao Li;
[email protected], Xue Chen;
[email protected], and Junsong Han;
[email protected] Received 23 June 2020; Revised 27 July 2020; Accepted 14 August 2020; Published 24 September 2020 Academic Editor: Mingjun Shi Copyright © 2020 Xiaona Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Prostate cancer (PCa) is one of the most commonly diagnosed cancers in males worldwide. lncRNAs (long noncoding RNAs) play a significant role in the occurrence and development of PCa. eRNAs (enhancer RNAs) and SE-lncRNAs (superenhancer lncRNAs) are important elements of lncRNAs, but the role of eRNAs and SE-lncRNAs in PCa remains largely unclear. In this work, we identified 681 eRNAs and 292 SE-lncRNAs that were expressed differentially in PCa using a microarray.